<DOC>
	<DOCNO>NCT01862328</DOCNO>
	<brief_summary>This open-label , multicenter , phase 1b , dose escalation study MLN4924 plus docetaxel , gemcitabine combination carboplatin paclitaxel adult patient solid tumor .</brief_summary>
	<brief_title>Dose Escalation , Multi-arm Study MLN4924 Plus Docetaxel , Gemcitabine , Combination Carboplatin Paclitaxel Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Male female patient 18 year age old ECOG PS 0 1 Patients must histologically cytologically confirm metastatic locally advanced incurable solid tumor felt appropriate treatment 1 3 chemotherapy regimen study , progress despite standard therapy , conventional therapy consider effective . The tumor must radiographically clinically evaluable and/or measurable Recovered effect prior antineoplastic therapy Female patient post menopausal , surgically sterile , agree practice 2 effective method contraception agree practice true abstinence Male patient agree practice effective barrier contraception agree practice true abstinence Voluntary write consent must give performance studyrelated procedure Suitable venous access studyrequired blood sample Adequate clinical laboratory value screen period specify protocol Patients willing refrain donate blood least 90 day final dose MLN4924 ( male patient ) willing refrain donate semen least 4 month final dose MLN4924 Availability fix tumor specimen ( block slide ) exploratory biomarker analysis . If slides block available , fresh tumor biopsy obtain used assessment Major surgery within 14 day first dose study drug Female patient lactate pregnant Active uncontrolled infection severe infectious disease Receiving antibiotic therapy within 14 day first dose study treatment Lifethreatening illness unrelated cancer Known hypersensitivity studyassigned chemotherapy Prior treatment MLN4924 ; however , prior treatment docetaxel , paclitaxel , carboplatin , gemcitabine allow History severe hypersensitivity reaction docetaxel ( polysorbate 80based formulation ) patient enrol Arm 1 ( MLN4924 + docetaxel ) , history hypersensitivity carboplatin patient enrol Arm 2 ( MLN4924 + paclitaxel + carboplatin ) , history severe hypersensitivity paclitaxel ( cremophorbased formulation ) patient enrol Arm 2 Persistent diarrhea ( great Grade 2 ) last &gt; 3 day within 2 week first dose study treatment Systemic antineoplastic therapy within 21 day first dose study drug Radiotherapy within 14 day precede first dose study treatment Prior treatment radiation therapy involve â‰¥ 25 % hematopoietically active bone marrow Treatment CYP3A inducer within 14 day first dose MLN4924 . Treatment CYP3A inhibitor within 14 day first dose MLN4924 ; however , voriconazole fluconazole need stop 3 day MLN4924 . Patients must history amiodarone use 6 month first dose MLN4924 Clinically uncontrolled central nervous system ( CNS ) involvement Any serious medical psychiatric illness Treatment investigational product 21 day prior treatment Patients currently take statin unwilling unable refrain use statin 24 hour , day , 24 hour MLN4924 administration Known human immunodeficiency virus ( HIV ) positive hepatitis B surface antigenpositive status , know suspect active hepatitis C infection Known hepatic cirrhosis Known cardiac/cardiopulmonary disease Left ventricular ejection fraction Patients cardiac pacer whose heart rate set fix rate patient concomitant medication may limit increase heart rate response hypotension History severe intolerance cytotoxic agent ( ) give assign arm</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>MLN4924</keyword>
	<keyword>Solid Tumors</keyword>
</DOC>